Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer

NCT01792050 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

169

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Docetaxel
OTHER: Placebo
DRUG: Indoximod
DRUG: Paclitaxel

Sponsor

NewLink Genetics Corporation